Screener
4D Molecular Therapeutics FDMT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $14,692 | $11,159 |
| Accrued and other current liabilities | 22,866 | 26,874 |
| Deferred revenue | 360 | 360 |
| Operating lease liabilities, current portion | 5,486 | 5,592 |
| Total current liabilities | 43,404 | 43,985 |
| Deferred revenue, net of current portion | 2,125 | 745 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's accrued expenses?
- 4D Molecular Therapeutics (FDMT) reported accrued expenses of $22.87M in Q1 2026.
- How has 4D Molecular Therapeutics's accrued expenses changed year-over-year?
- 4D Molecular Therapeutics's accrued expenses increased by 41.1% year-over-year, from $16.2M to $22.87M.
- What is the long-term trend for 4D Molecular Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's accrued expenses has grown at a 26.3% compound annual growth rate (CAGR), from $8.37M to $26.87M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about 4D Molecular Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude